Previous 10 | Next 10 |
Gainers: Stewardship Financial (NASDAQ: SSFN ) +73% . Beyond Meat (NASDAQ: BYND ) +36% . La Jolla Pharmaceutical (NASDAQ: LJPC ) +25% . ReWalk Robotics (NASDAQ: RWLK ) +26% . Neptune Wellness Solutions (NASDAQ: NEPT ) +21% . Zoom Video Communications (NASDAQ: ZM ) +21% . Horizo...
Gainers: La Jolla Pharmaceutical (NASDAQ: LJPC ) +87% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +74% . Ciena Corporation (NYSE: CIEN ) +24% . Cidara Therapeutics (NASDAQ: CDTX ) +21% . Dynatronics Corporation (NASDAQ: DYNT ) +16% . Stitch Fix (NASDAQ: SFIX ) +15% . Eloxx Phar...
ContraVir Pharmaceuticals (NASDAQ: CTRV ) +123% on encouraging CRV431 data . More news on: ContraVir Pharmaceuticals, Inc., Stitch Fix, Inc., Ciena Corporation, Stocks on the move, Read more ...
Thinly traded nano cap ContraVir Pharmaceuticals (NASDAQ: CTRV ) is up 139% premarket on increased volume in reaction to positive preclinical data on NASH candidate CRV431. More news on: ContraVir Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Healthcare stocks news,...
EDISON, N.J., June 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...
Aimed at regaining compliance with Nasdaq listing requirements, ContraVir Pharmaceuticals (NASDAQ: CTRV ) has announced a 1:70 reverse split of its common stock, effective May 31. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read mor...
EDISON, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, a...
EDISON, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today...
Nano cap ContraVir Pharmaceuticals (NASDAQ: CTRV ) slumps 51% premarket on modest volume in reaction to its public offering of Class A and Class B Units. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
EDISON, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs...
News, Short Squeeze, Breakout and More Instantly...
ContraVir Pharmaceuticals Inc. Company Name:
CTRV Stock Symbol:
NASDAQ Market:
ContraVir Pharmaceuticals Inc. Website:
EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...
ContraVir Pharmaceuticals (NASDAQ: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, has closed an underwritten public offering res...
EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...